Expanded Access Treatment Protocol CA204-143

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Men and women 18 years and older

- Active, relapsed or refractory multiple myeloma by IMWG (International myeloma
Working Group) criteria as assessed by the treating physician and have received one
prior line of multiple myeloma therapy

- Prior lenalidomide exposure is permitted only if they fulfill all of the following:

- i)Were not refractory to prior lenalidomide defined as no progression while
receiving lenalidomide (induction dose) or within 60 days of last dose of
lenalidomide. Patients progressing on lenalidomide maintenance dose are eligible
for enrolment.

- ii) Patient did not discontinue lenalidomide due to a Grade ≥ 3 related AE

Exclusion Criteria:

- Active plasma cell leukemia (defined as either 20% of peripheral WBC comprised of
plasma/CD138+ cells or an absolute count of 2 x 109/L).

- All Adverse Events of any prior chemotherapy, surgery, or radiotherapy not resolved
to NCI CTCAE (v. 3.0) Grade ≤ 2

- Significant cardiac disease as determined by the treating physician including cardiac
amyloidosis

- HIV infection or active hepatitis A, B, or C

- History of participation in elotuzumab studies CA204-004, CA204-006 or CA204-009

- Inadequate recovery from prior surgery or prior myeloma therapy. If prior allogeneic
stem cell transplant, history of moderate to severe chronic graft versus host disease
(GvHD)

- Any medical conditions that, in the attending physician's opinion, would impose
excessive risk to the patient

- Certain abnormal physicial or laboratory findings

- Hypersensitivity to lenalidomide, dexamethasone, any excipients in the elotuzumab
formulation, or recombinant protein